Literature DB >> 27686376

Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Sebastian Giebel1, Myriam Labopin2,3, Gerard Socié4, Dietrich Beelen5, Paul Browne6, Liisa Volin7, Slawomira Kyrcz-Krzemien8, Ibrahim Yakoub-Agha9, Mahmoud Aljurf10, Depei Wu11, Mauricette Michallet12, Renate Arnold13, Mohamad Mohty2, Arnon Nagler3,14.   

Abstract

Allogeneic hematopoietic cell transplantation is widely used to treat adults with high-risk acute lymphoblastic leukemia. The aim of this study was to analyze whether the results changed over time and to identify prognostic factors. Adult patients treated between 1993 and 2012 with myeloablative allogeneic hematopoietic cell transplantation from HLA matched sibling (n=2681) or unrelated (n=2178) donors in first complete remission were included. For transplantations from sibling donors performed between 2008 and 2012, 2-year probabilities of overall survival were: 76% (18-25 years old), 69% (26-35 and 36-45 years old) and 60% (46-55 years old). Among recipients of transplantations from unrelated donors, the respective survival rates were 66%, 70%, 61%, and 62%. In comparison with the 1993-2007 period, significant improvements were observed for all age groups except for the 26-35-year old patients. In a multivariate model, transplantations performed between 2008 and 2012, when compared to 1993-2007, were associated with significantly reduced risks of non-relapse mortality (Hazard Ratio 0.77, P=0.00006), relapse (Hazard Ratio 0.85, P=0.007), treatment failure (Hazard Ratio 0.81, P<0.00001), and overall mortality (Hazard Ratio 0.79, P<0.00001). In the analysis restricted to transplantations performed between 2008 and 2012, the use of total body irradiation-based conditioning was associated with reduced risk of relapse (Hazard Ratio 0.48, P=0.004) and treatment failure (Hazard Ratio 0.63, P=0.02). We conclude that results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia improved significantly over time. Total body irradiation should be considered as the preferable type of myeloablative conditioning. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27686376      PMCID: PMC5210244          DOI: 10.3324/haematol.2016.145631

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  22 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

2.  Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia.

Authors:  S M Davies; N K Ramsay; J P Klein; D J Weisdorf; B Bolwell; J Y Cahn; B M Camitta; R P Gale; S Giralt; C Heilmann; P J Henslee-Downey; R H Herzig; R Hutchinson; A Keating; H M Lazarus; G A Milone; S Neudorf; W S Perez; R L Powles; H G Prentice; G Schiller; G Socié; M Vowels; J Wiley; A Yeager; M M Horowitz
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

3.  Survival improvements in adolescents and young adults after myeloablative allogeneic transplantation for acute lymphoblastic leukemia.

Authors:  William A Wood; Stephanie J Lee; Ruta Brazauskas; Zhiwei Wang; Mahmoud D Aljurf; Karen K Ballen; David K Buchbinder; Jason Dehn; Cesar O Freytes; Hillard M Lazarus; Charles F Lemaistre; Paulette Mehta; David Szwajcer; Steven Joffe; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-07       Impact factor: 5.742

Review 4.  Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults.

Authors:  Craig Speziali; Kristjan Paulson; Matthew Seftel
Journal:  Curr Hematol Malig Rep       Date:  2016-06       Impact factor: 3.952

5.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.

Authors:  P L Weiden; N Flournoy; E D Thomas; R Prentice; A Fefer; C D Buckner; R Storb
Journal:  N Engl J Med       Date:  1979-05-10       Impact factor: 91.245

6.  Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  A Gratwohl; J Hermans; J M Goldman; W Arcese; E Carreras; A Devergie; F Frassoni; G Gahrton; H J Kolb; D Niederwieser; T Ruutu; J P Vernant; T de Witte; J Apperley
Journal:  Lancet       Date:  1998-10-03       Impact factor: 79.321

7.  Comparison of total body irradiation plus cyclophosphamide with busulfan plus cyclophosphamide as conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant.

Authors:  Celalettin Eroglu; Cigdem Pala; Leylagül Kaynar; Kadir Yaray; M Tarkan Aksozen; Mehmet Bankir; Gökmen Zararsız; Okan Orhan; Mete Gündog; Oguz G Yıldız; Bülent Eser; Mustafa Cetin; Ali Unal
Journal:  Leuk Lymphoma       Date:  2013-03-27

8.  Impact of a donor source on adult Philadelphia chromosome-negative acute lymphoblastic leukemia: a retrospective analysis from the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Authors:  S Nishiwaki; K Miyamura; K Ohashi; M Kurokawa; S Taniguchi; T Fukuda; K Ikegame; S Takahashi; T Mori; K Imai; H Iida; M Hidaka; H Sakamaki; Y Morishima; K Kato; R Suzuki; J Tanaka
Journal:  Ann Oncol       Date:  2013-01-31       Impact factor: 32.976

9.  Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia.

Authors:  H Pfeifer; B Wassmann; W Bethge; J Dengler; M Bornhäuser; M Stadler; D Beelen; V Vucinic; T Burmeister; M Stelljes; C Faul; P Dreger; A Kiani; K Schäfer-Eckart; R Schwerdtfeger; E Lange; B Kubuschok; H A Horst; M Gramatzki; P Brück; H Serve; D Hoelzer; N Gökbuget; O G Ottmann
Journal:  Leukemia       Date:  2012-12-05       Impact factor: 11.528

10.  Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome.

Authors:  Michael B Tomblyn; Mukta Arora; K Scott Baker; Bruce R Blazar; Claudio G Brunstein; Linda J Burns; Todd E DeFor; Kathryn E Dusenbery; Dan S Kaufman; John H Kersey; Margaret L MacMillan; Philip B McGlave; Jeffrey S Miller; Paul J Orchard; Arne Slungaard; Marcie R Tomblyn; Gregory M Vercellotti; Michael R Verneris; John E Wagner; Daniel J Weisdorf
Journal:  J Clin Oncol       Date:  2009-07-06       Impact factor: 44.544

View more
  20 in total

1.  New insights into effective targeted therapy for the treatment of adult acute lymphoblastic leukemia.

Authors:  Xavier Thomas
Journal:  Int J Hematol Oncol       Date:  2017-05-18

2.  How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT.

Authors:  Olaf Penack; Christophe Peczynski; Mohamad Mohty; Ibrahim Yakoub-Agha; Jan Styczynski; Silvia Montoto; Rafael F Duarte; Nicolaus Kröger; Hélène Schoemans; Christian Koenecke; Zinaida Peric; Grzegorz W Basak
Journal:  Blood Adv       Date:  2020-12-22

3.  Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation.

Authors:  Anne Banet; Ali Bazarbachi; Myriam Labopin; Nicolas Stocker; Rémy Duléry; Florent Malard; Zoé Van de Wyngaert; Alexis Genthon; Mara Memoli; Ollivier Legrand; Agnes Bonnin; Tounes Ledraa; Ramdane Belhocine; Simona Sestili; Jean El-Cheikh; Mohamad Mohty; Eolia Brissot
Journal:  Bone Marrow Transplant       Date:  2022-10-12       Impact factor: 5.174

4.  CNS Involvement at Initial Diagnosis and Risk of Relapse After Allogeneic HCT for Acute Lymphoblastic Leukemia in First Complete Remission.

Authors:  Mohamed A Kharfan-Dabaja; Myriam Labopin; Ali Bazarbachi; Urpu Salmenniemi; Stephan Mielke; Patrice Chevallier; Marie Thérèse Rubio; Marie Balsat; Pietro Pioltelli; Anne-Lise Menard; Gerard Socié; Anne Huynh; Nicolaas Schaap; Arancha Bermúdez Rodríguez; Jan J Cornelissen; Ibrahim Yakoub-Agha; Mahmoud Aljurf; Sebastian Giebel; Eolia Brissot; Zina Peric; Arnon Nagler; Mohamad Mohty
Journal:  Hemasphere       Date:  2022-10-12

5.  Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Arnon Nagler; Myriam Labopin; Ryszard Swoboda; Pietro Pioltelli; Mutlu Arat; Ibrahim Yakoub-Agha; Alexander Kulagin; Anna Maria Raiola; Hakan Ozdogu; Antonio Risitano; Zubeyde Nur Ozkurt; Jaime Sanz; Eolia Brissot; Peric Zina; Sebastian Giebel; Fabio Ciceri; Mohamad Mohty
Journal:  Hemasphere       Date:  2022-10-13

6.  Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT.

Authors:  Sebastian Giebel; Myriam Labopin; Gerard Socié; David Beauvais; Stefan Klein; Eva Maria Wagner-Drouet; Didier Blaise; Stephanie Nguyen-Quoc; Jean Henri Bourhis; Anne Thiebaut; Hélène Labussière-Wallet; Amandine Charbonnier; Ana Berceanu; José Luis Diez-Martin; Nathalie Fegueux; Jordi Esteve; Arnon Nagler; Mohamad Mohty
Journal:  Bone Marrow Transplant       Date:  2020-11-25       Impact factor: 5.483

7.  Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party.

Authors:  Mohamad Mohty; Arnon Nagler; Eolia Brissot; Myriam Labopin; Domenico Russo; Sonja Martin; Christoph Schmid; Bertram Glass; Ron Ram; Zubeyde Nur Ozkurt; Jakob Passweg; Joan Hendrik Veelken; Donald Bunjes; Jane Apperley; Sebastian Giebel
Journal:  Bone Marrow Transplant       Date:  2020-03-17       Impact factor: 5.483

Review 8.  Indications for Allogeneic HCT in Adults with Acute Lymphoblastic Leukemia in First Complete Remission.

Authors:  Shukaib Arslan; Vinod Pullarkat; Ibrahim Aldoss
Journal:  Curr Treat Options Oncol       Date:  2021-06-07

9.  Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia.

Authors:  C Greil; M Engelhardt; G Ihorst; J Duque-Afonso; K Shoumariyeh; H Bertz; R Marks; R Zeiser; J Duyster; J Finke; R Wäsch
Journal:  Bone Marrow Transplant       Date:  2020-10-31       Impact factor: 5.483

10.  Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT.

Authors:  Gabrielle Roth-Guepin; Jonathan Canaani; Annalisa Ruggeri; Myriam Labopin; Juergen Finke; Jan J Cornelissen; Jeremy Delage; Gernot Stuhler; Monserrat Rovira; Mike Potter; Michael Stadler; Hendrik Veelken; Jean Yves Cahn; Matthew Collin; Yves Beguin; Sebastian Giebel; Arnon Nagler; Mohamad Mohty
Journal:  Oncotarget       Date:  2017-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.